Solara Active Pharma Sciences Limited has issued a comprehensive postal ballot notice dated February 04, 2026, seeking shareholder approval for the appointment of Mr. Mohanraj Sanjeevi as Whole-time Director, establishing a structured timeline for electronic voting and regulatory compliance.

Postal Ballot Process and Timeline

The company has established a detailed schedule for the postal ballot process, with all communications being conducted electronically in compliance with regulatory requirements under the Companies Act, 2013 and SEBI regulations.

The postal ballot notice has been sent electronically to all members whose names appear in the Register of Members/List of Beneficial Owners as received from depositories as on the cut-off date. The company has appointed Mr. Preetham Hebbar (CoP No. 21431) of M/s. Preetham Hebbar & Co., Practicing Company Secretaries, as the Scrutinizer for conducting the postal ballot e-voting process.

Director Appointment and Regulatory Compliance

The special resolution seeks approval for the appointment of Mr. Mohanraj Sanjeevi (DIN: 08420411) as Whole-time Director (Executive Director) of the Company. The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, had appointed Mr. Sanjeevi as an Additional Director with effect from January 01, 2026, subject to shareholder approval.

Pursuant to Regulation 17(1C) of SEBI Listing Regulations, approval of members is required for board appointments within three months from the date of appointment, necessitating this postal ballot process.

Professional Background and Qualifications

Mr. Mohanraj Sanjeevi brings extensive experience to the role, with over three decades of expertise across pharmaceutical, biotech, defence & aerospace, engineering, apparel, and media sectors. His professional qualifications include deep expertise in industrial relations strategy, workforce governance, statutory and regulatory compliance, and organizational leadership.

Comprehensive Remuneration Structure

The Board has recommended a structured remuneration package for Mr. Sanjeevi, designed to align with industry standards for similar executive roles.

The variable pay component will be calculated based on individual performance and organizational/business unit performance metrics. Additional benefits include insurance coverage, leave encashment, travel reimbursement, company car usage, and corporate credit card facility.

E-voting Process and Accessibility

Shareholders can participate in the e-voting process through the platform provided by Central Depository Services (India) Limited (CDSL). The company has ensured compliance with all applicable circulars issued by the Ministry of Corporate Affairs and SEBI regulations.

Individual shareholders holding securities in demat mode can vote through their demat accounts, while those holding shares in physical form can access the voting platform directly through CDSL's e-voting system using their folio numbers.

Company Financial Context and Strategic Focus

The appointment comes as the company continues implementing various corrective measures to improve financial performance, including product portfolio rationalization with focus on higher-margin products and cost-optimization initiatives.

The company has witnessed improvement in gross margins and positive EBITDA, with expectations of enhanced productivity levels and gradual improvement in profitability through continued emphasis on efficiency and improved product mix. The resolution, if approved by the requisite majority, will be deemed to have been passed on March 06, 2026, the last date of remote e-voting.

Solara Active Pharma Sciences Limited has issued a revised intimation regarding its upcoming conference call with analysts and investors to discuss Q3FY26 financial results. The pharmaceutical company filed the updated notification with BSE and NSE on February 03, 2026, announcing a change in the timing of the previously scheduled earnings call.

Revised Conference Call Details

The company has updated the earnings call schedule with the following revised specifications:

Key Management Participation

The earnings call will feature senior management representatives who will discuss the company's performance:

• Arun Kumar - Founder & Non-Executive Director
• Sandeep Rao - Managing Director & CEO
• Sarat Kumar - Chief Financial Officer

Financial Results Coverage

The conference call will cover Solara Active Pharma Sciences' unaudited financial results for the quarter and nine months ended December 31, 2025. This represents the company's Q3FY26 performance, providing insights into the pharmaceutical company's operational and financial metrics during this period.

Access Information

The company has provided multiple access options for participants:

The revised intimation was signed by Pooja Jaya Kumar, Company Secretary & Compliance Officer (Membership No: A57415), and filed under Regulation 30 compliance requirements with both BSE (Scrip Code: 541540, 890202) and NSE (Symbol: SOLARA, SOLARAPPI). All other details from the original intimation dated January 30, 2026, remain unchanged except for the timing modification.